UHR-OCT and HD-OCT for Preretinal Membranes: ICG Versus Membrane Blue

Condition(s) targeted: Retinal Diseases

Intervention: ppVE, MP, ICG (Procedure); ppVE, MP, MB (Procedure)

Phase: N/A

Status: Recruiting

Sponsored by: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Official(s) and/or principal investigator(s):
Susanne Binder, MD, Study Chair, Affiliation: Ludwig Boltzmann Institue for Retinology and Biomicroscopic Lasersurgery

Overall contact:
Susanne Binder, MD, Phone: +431711654607, Email: susanne.binder@wienkav.at

Using the UHR-OCT and HD-OCT to evaluate early postoperative changes in patients with diagnosis preretinal membrane after successfully performed pars-plana vitrectomy and membrane peeling with two different types of dyes.

Official title: UHR-OCT and HD-OCT for Preretinal Membranes: Is There a Difference Between ICG and Membrane Blue? A Randomized Clinical Trial

Study design: Diagnostic, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome:

UHR-OCT HD-OCT

Distance Visual acuity

Near Visual acuity

Contrast sensitivtiy

Secondary outcome:

OCT Stratus 3000

Visual Field

Detailed description: Surgical procedures performed are pars-plana vitrectomy and membrane peeling with or without cataract extraction and IOL implantation. The type of the dyes is randomized. The study is designed to include a total of tweny cases (10 cases with ICG and 10 cases with Membrane blue)

Main outcome measures are:

UHR-OCT, HD-OCT distance and near visual acuity and contrast sensitivity amsler grid secondary outcome measures are: OCT Stratus 3000 and visual field. Clinical examinations: preoperative, and follow-up examinations after 1 week, 1 months, 3 months, 6 months and 12 months.

Minimum age: 18 Years. Maximum age: 85 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Preretinal membrane

- Age between 18 and 85 years

- Combined surgery possible(phacoemulsification and vitreoretinal procedure)

Exclusion Criteria:

- Age-related macular degeneration

- Previous retinal detachment surgery

- Previous laser treatment

Susanne Binder, MD, Phone: +431711654607, Email: susanne.binder@wienkav.at

Rudolf Foundation Clinic, Vienna 1030, Austria; Recruiting
Susanne Binder, MD, Phone: +431711654607, Email: susanne.binder@wienkav.at
Christiane i Falkner-Radler, MD, Phone: +431711654607, Email: christiane.falkner-radler@wienkav.at
Susanne Binder, MD, Principal Investigator

Starting date: September 2005
Ending date: February 2009
Last updated: December 7, 2007